Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinfukang Oral Liquid plus first-line chemotherapy for driver gene-negative advanced non-small cell lung cancer
ChiCTR2400082057Phase 3Recruiting
- Sponsor
- Longhua Hospital Shanghai University of Traditional Chinese Medicine
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of jinfukang in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Longhua Hospital Shanghai University of Traditional Chinese Medicine. Primary endpoint: Progression-free survival. Started Mar 2024; status: recruiting.
02
Drugs
jinfukang
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400082057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082057.